In the 1980s the pharmaceutical industry was extremely critical of the Medicines Division and, by implication, of the Minister of State for Health, for the delays in processing their applications for product licences. In 1987, the average time taken to approve a licence application for a new chemical entity (NCE) was 18 months and for amendments to product licences was 8 months'. The Government's response to this mounting criticism by the pharmaceutical industry was the usual one of setting up an enquiry, in this case to examine the processing of product licence applications and of other work undertaken by the Medicines Division, as it then was. John Evans and Peter Cunliffe were chosen for the enquiry, started their work in April 1987 and issued their report'', known colloquially as the Evans/Cunliffe Report, in December of the same year, a commendably rapid reaction. In April 1988, the Minister of State for Health announced his decision on the recommendations made in the report. This meeting of the Library (Scientific Research) Section was held to review the background to the report, its recommendations and their implementation.
The Evans/Cunliffe report The first speaker, Mr Brian Rayner (Deputy Secretary in the Department of Health) has many years of experience as a civil servant and was eminently qualified to give the background to the Evans/Cunliffe Report. He became involved with relationships between the pharmaceutical industry and the Department of Health in October 1984, at about the time that Mr Norman Fowler proposed the introduction of limited lists. Perhaps the concern and the debate over this contentious topic, and the subsequent negotiations on the Pharmaceutical Price Regulation Scheme (PPRS), concealed the pharmaceutical industry's disquiet about licensing delays because he claimed not to have detected any marked anxiety at that time. However, it was not long before the pharmaceutical industry's problems of loss of patent life, with consequent effect on investment and profits, and loss of exports were being stressed as repercussions of the delays in granting product licences. The growing criticism affected morale in the Medicines Division, who were also concerned about the possibility that useful medicines were being denied to patients.
A major factor contributing to the delays was the increase in licensing work, which was estimated at a compound rate of 5% between 1976 and 1987, without any corresponding increase in resources. Although the Medicines Division had increased its productivity, an unacceptable backlog of product licence applications developed. An increase of 10% in the professional staff of the Medicines Division was agreed but this was never implemented owing to the reductions in staffing levels, of about 20% over 3 years, imposed on the civil service in the 1980s. The impossible situation of an increasing workload of product licence applications and restrictions on the recruitment of professional staff was a strong influence on the decision to seek independent advice on resolving the problem. The choice of John Evans and Peter Cunliffe brought in knowledge and experience of commercial operations in the private sector and familiarity with the problems of the pharmaceutical industry in their dealings with the Medicines Division. Their terms of reference were to examine the issues for the Department of Health arising from the continued increase in product licence and other work in the Medicines Division and to recommend ways to deal expeditiously with this work while maintaining adequate standards for the safety, efficiency and quality of human medicines in the United Kingdom.
The Evans/Cunliffe Report, issued in December 1987, was complimentary about the professional aspects of the work of the Medicines Division, confirmed that the licensing authority in the United Kingdom had a high reputation internationally and that the standards set by the licensing authority were not unduly high as most of the requirements of the Medicines Division would be carried out as a matter of course in the development of a new medicine. However, there were 54 recommendations for improvement, including a few addressed to the pharmaceutical industry itself. The most important of the recommendations concerned the organization and management of the tasks and functions of the Medicines Division. The principal recommendation was that the staff of Medicines Division should be brought into one organization under a single head and the organization should be on functional lines. Conditions of employment and establishment levels were other fundamental aspects on which important recommendations were made. The principal recommendations ofthe report were accepted in April 1988.
The pharmaceutical industry indicated their preparedness to pay higher licensing fees if the licensing times were substantially reduced. Up to 1987,60% of the costs of the Medicines Division were funded by licensing fees and the Evans/Cunliffe Report proposed the changes to complete funding of the Medicines Division from licensing fees, a change which was implemented by April 1989 when a new tariff of fees was introduced. This was, incidentally, also seen as a circumvention of government control on establishment and its replacement with a more flexible budgetary discipline, although the proposal to do this through a budgetary committee was rejected. Thus, the new organization, the Medicines Control Agency with a staff of 300, was born and Dr Keith Jones was appointed its Director. One adverse consequence of the changes was a deluge of product licence applications in March 1988, six times the usual number, aimed at pre-empting the revised fee structure. The result was a major shortfall in the revenues budgeted for in the period 1989/1990 and a 70% increase in fees in March 1990. A legal challenge by some pharmaceutical companies was successfully resisted but it delayed the introduction of a new range of differential fees.
MCA is a division within the Department of Health and there is no intention of changing this situation. After all, it is the Minister who actually issues product licences on the advice and recommendation of the Committee on Safety of Medicines (CSM). The MCA faces considerable change in the coming years and Dr Jones hoped that the re-organization which has already taken place and which is now being consolidated will enable the MCA to react appropriately and maintain its flexibility. As the backlog of licensing work is eliminated and the single European market becomes a reality, the pattern of working within the MCA will undergo profound change.
The MCA, as presently constituted comprises 'six major businesses', as they were designated by Dr Jones; each business group is managed by a Business Manager who is selected on his management ability. Dr Jones claimed that it was fortuitous that these included two physicians, two pharmacists and two administrators. Four of the six businesses are directly concerned with licensing activities: approving new chemical entities (NCEs); abridged licence applications; pharmacovigilance, that is, surveillance for ADRs; and inspection of manufacturer's premises and processes. Of the other two businesses, one is concerned with policy, administration, finance and information technology and the other with the British Pharmacopoeia.
During the past year there had been a 30% improvement in the overall licensing performance and, for NCEs, the MCA is now the quickest licensing authority in Europe. The internal assessment time between receipt of a submission and recommendation to the CSM has been reduced from 154 to 93 working days and the time to a hearing to 75 days. The target of a 66% improvement in performance in dealing with abridged licence applications was met despite a deluge of applications designed to avoid increases in fees and the poor quality of many of the submissions which necessarily increased the professional time devoted to them. The target of a 44% improvement in processing variations to product licences was exceeded. Targets for dealing with abridged product licences during the coming 18 months were shown as:
In addition to meeting these targets and eliminating the backlog of applications, a matter of high priority is to achieve financial stability. Dr Jones is aware of the concern over fees but pointed out that the running costs of the MCA were lower than those of comparable research organizations and industry associations. Quality control measures will be strengthened to ensure that high standards are not sacrificed to turnover times. But perhaps the most significant factor for the future will be the harmonization of The Medicines Control Agency Dr Keith Jones had 23 years' experience in the pharmaceutical industry before he was appointed the first Director of the Medicines Control Agency (MCA) in April 1989. Dr Jones opened by stating the function of the MCA was essentially the protection of public health through the control of medicines. The objectives of the MCA are to ensure that all medicines in the United Kingdom meet acceptable standards of quality, safety and efficacy, and that appropriate licences are granted promptly and without unnecessary impediment to the pharmaceutical industry. The responsibilities of the MCA are much broader than simply the issuing of licences; they include the inspection of the manufacture of medicines, surveillance of adverse drug reactions (ADRs), the publication of standards through the British Pharmacopoeia and parliamentary support work. These were illustrated with examples of the interaction between the MCA and other organizations and committees during which it was stressed that the European product licensing procedures. More than 40% of the current European multistate licensing work is carried out by the MCA so it is experienced and well placed for any future changes in procedures and should be able to cope with the imminent increase in work incurred by European directives on leaflets and labelling. Whether the proposed European Medicines Evaluation Agency will be sited in the United Kingdom will probably not depend on objective assessment of experience or efficacy but on a political decision.
The view of the pharmaceutical industry The pharmaceutical industry's impressions of the period since the Evans/Cunliffe Report were given at short notice by Dr Brian Gennery (Group Medical Director (Europe) of Eli Lilly). He sent a questionnaire to the 14 members of the Me~i~al Committee of the ABPI (Association of the British Pharmaceutical Industry) which was designed to elicit their perceptions of the MCA's performance since its inception. . The targets set for issuing clinical trial exemption certificates (CTXs) were largely being met; the time was exceeded in only 2% of cases and in these there were usually reasons for the longer time and a need for some dialogue between the applicant and the agency.
. The necessity to ask chemical and pharmaceutical questions of the applicant often explained a delay in dealing with variations to CTXs but some of the questions which had been asked seemed inappropriate for the early stage of development of a medicine. There was general satisfaction with the processing of licence applications for NCEs with the majority of them passing through the MCA to the Committee on Safety of Medicines (CSM) within 6-7 months. The issue of conditional product licences is generally welcomed by the pharmaceutical industry and may be one of the reasons why no Section 21.1 letters refusing a licence appear to have been issued to the respondents recently. The cancellation of licence hearings at short notice caused some frustration despite the fact that the reason was usually the imminent release of a product licence.
The greatest concern was expressed over the serious delays in issuing abridged product licences. Despite the targets for improvement set by the MCA, the answers to the questionnaires showed a lack of conviction among the participating executives in the pharmaceutical industry for a rapid improvement.
The pharmaceutical industry welcomed the MCA acting as the sponsor for multistate licensing applications in Europe and acknowledged that the staff at the MCA took their responsibilities for European procedures very seriously.
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The questionnaire did not include anything on the issue oflicensing fees but that did not preclude some observations being made. Obviously, these comments were of concern about the recent substantial increases in fees which made the United Kingdom the most expensive country in Europe for processing product licence applications.
In reviewing the information obtained from his questionnaire, Dr Gennery made six general observations, three pertaining to the pharmaceutical industry and three to the MCA:
(i) Pharmaceutical companies should ensure that they submit a dossier of the highest quality. (ii) The science in the dossier must be adequate for the task. (iii) The presentation of the dossier should be attractive, that is, well written with relevant tables and good graphics. (iv) The MCA needs to present itself as a service organization with the consequent change in attitudes that this implies. (v) There should be better scope for discussing a licensing application with the professional staff of the MCA without this opportunity being abused by the pharmaceutical industry. (vi) The time for processing abridged licence applications needs to be reduced quickly and substantially. In conclusion, the pharmaceutical industry is clearly ofthe opinion that, since the establishment of the MeA, the handling of product licence applications is very much better.
Postscript
Mr Rayner and Dr Jones showed courage in attending a meeting composed mainly of representatives from the pharmaceutical industry and offering themselves as targets for the industry's criticism. However, they were both clearly confident that the reforms which evolved from the Evans/Cunliffe Report and the recent performance of the MCA would be more than adequate as a defence against any attack that might unfold, and so it proved. Perhaps Dr Jones would be comforted by a saying of Seneca:
'Peoplepay the doctor for his trouble; for his kindness they still remain in his debt.' P J Keen Editorial Representative Library (Scientific Research) Section
